Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06843044 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 28 words
    • Study title revised
    v3
  2. Secondary endpoints revised (53)v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Valenta Pharm JSC
13 trials monitored
See all monitored trials
Anxiety
3,263 trials monitored
See 159 trials at risk
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.
Trial Details
NCT Number NCT06843044
Lead Sponsor Valenta Pharm JSC
Conditions
(from sponsor)		 Anxiety, Neurasthenia, Adjustment Disorders
Related terms Adjustment Disorders, Anxiety Disorders, Neurasthenia
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov